Study reports benefits of aspirin plus Plavix
This article was originally published in The Tan Sheet
A study shows patients with atrial fibrillation reduced their risk of major vascular events by 11 percent by taking Plavix (clopidogrel) plus aspirin compared to aspirin alone. The results "suggest a potential change in clinical practice," says a study investigator. Findings announced March 31 from the ACTIVE A (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Cardiovascular Events) phase III double-blind, placebo-controlled trial also said the heart arrhythmia patients taking the antiplatelet drug and aspirin saw a 28 percent reduction in stroke during the median 3.6 years of follow-up. Bristol-Myers Squibb and Sanofi-Aventis, which jointly market Plavix, sponsored the study. Atrial fibrillation patients have a five-fold greater stroke risk and cannot take oral anticoagulants, a researcher said. A 2007 analysis found aspirin alone is more effective than Plavix and other Rx antiplatelets in preventing first or repeat heart attack or stroke (1"The Tan Sheet" April 23, 2007, p. 10)
You may also be interested in...
Aspirin is the blood thinning agent of choice over three prescription antiplatelet medications for preventing first or repeat heart attack or stroke, according to a Consumers Union report
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.